183 related articles for article (PubMed ID: 23613854)
41. Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon gamma in renal cell carcinoma cell lines.
Ikemoto S; Sugimura K; Yoshida N; Kuratsukuri K; Wada S; Nakatani T
Anticancer Res; 2002; 22(6C):4023-7. PubMed ID: 12553027
[TBL] [Abstract][Full Text] [Related]
42. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
[TBL] [Abstract][Full Text] [Related]
43. CD70: a new tumor specific biomarker for renal cell carcinoma.
Junker K; Hindermann W; von Eggeling F; Diegmann J; Haessler K; Schubert J
J Urol; 2005 Jun; 173(6):2150-3. PubMed ID: 15879877
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.
Huang D; Ding Y; Luo WM; Bender S; Qian CN; Kort E; Zhang ZF; VandenBeldt K; Duesbery NS; Resau JH; Teh BT
Cancer Res; 2008 Jan; 68(1):81-8. PubMed ID: 18172299
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Vaziri SA; Grabowski DR; Hill J; Rybicki LR; Burk R; Bukowski RM; Ganapathi MK; Ganapathi R
Anticancer Res; 2009 Aug; 29(8):2961-9. PubMed ID: 19661301
[TBL] [Abstract][Full Text] [Related]
46. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
Pal SK; Forero-Torres A; Thompson JA; Morris JC; Chhabra S; Hoimes CJ; Vogelzang NJ; Boyd T; Bergerot PG; Adashek JJ; Li H; Yu X; Gartner EM; Carret AS; Smith DC
Cancer; 2019 Apr; 125(7):1124-1132. PubMed ID: 30624766
[TBL] [Abstract][Full Text] [Related]
47. Tumor necrosis factor-α induces epithelial-mesenchymal transition of renal cell carcinoma cells via a nuclear factor kappa B-independent mechanism.
Wu ST; Sun GH; Hsu CY; Huang CS; Wu YH; Wang HH; Sun KH
Exp Biol Med (Maywood); 2011 Sep; 236(9):1022-9. PubMed ID: 21856755
[TBL] [Abstract][Full Text] [Related]
48. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
[TBL] [Abstract][Full Text] [Related]
49. The emerging role of nuclear factor kappa B in renal cell carcinoma.
Morais C; Gobe G; Johnson DW; Healy H
Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
[TBL] [Abstract][Full Text] [Related]
50. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
Riesenberg R; Weiler C; Spring O; Eder M; Buchner A; Popp T; Castro M; Kammerer R; Takikawa O; Hatz RA; Stief CG; Hofstetter A; Zimmermann W
Clin Cancer Res; 2007 Dec; 13(23):6993-7002. PubMed ID: 18056175
[TBL] [Abstract][Full Text] [Related]
51. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12.
Ulchaker J; Panuto J; Rayman P; Novick A; Elson P; Tubbs R; Finke JH; Bukowski RM
J Immunother; 1999 Jan; 22(1):71-9. PubMed ID: 9924702
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of bortezomib for patients with advanced renal cell carcinoma.
Kondagunta GV; Drucker B; Schwartz L; Bacik J; Marion S; Russo P; Mazumdar M; Motzer RJ
J Clin Oncol; 2004 Sep; 22(18):3720-5. PubMed ID: 15365068
[TBL] [Abstract][Full Text] [Related]
53. Sodium butyrate inhibits interferon-gamma induced indoleamine 2,3-dioxygenase expression via STAT1 in nasopharyngeal carcinoma cells.
He YW; Wang HS; Zeng J; Fang X; Chen HY; Du J; Yang XY
Life Sci; 2013 Oct; 93(15):509-15. PubMed ID: 23942267
[TBL] [Abstract][Full Text] [Related]
54. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
55. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
[TBL] [Abstract][Full Text] [Related]
56. Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.
Kao C; Chao A; Tsai CL; Lin CY; Chuang WC; Chen HW; Yen TC; Wang TH; Lai CH; Wang HS
Cell Death Dis; 2013 Feb; 4(2):e512. PubMed ID: 23449448
[TBL] [Abstract][Full Text] [Related]
57. Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia.
Kulling PM; Olson KC; Hamele CE; Toro MF; Tan SF; Feith DJ; Loughran TP
PLoS One; 2018; 13(2):e0193429. PubMed ID: 29474442
[TBL] [Abstract][Full Text] [Related]
58. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
59. Interaction of retinoic acid and interferon in renal cancer cell lines.
Nanus DM; Geng Y; Shen R; Lai HK; Pfeffer SR; Pfeffer LM
J Interferon Cytokine Res; 2000 Sep; 20(9):787-94. PubMed ID: 11032398
[TBL] [Abstract][Full Text] [Related]
60. Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-gamma, but not IFN-alpha, signaling.
Takaoka A; Tanaka N; Mitani Y; Miyazaki T; Fujii H; Sato M; Kovarik P; Decker T; Schlessinger J; Taniguchi T
EMBO J; 1999 May; 18(9):2480-8. PubMed ID: 10228162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]